138343-77-8

Basic information

• Product Name: 1-Boc-7-azaindole
• Synonyms: 1-BOC-7-AZAINDOLE;1-BOC-7-AZAINDOLE, 98+%;7-Azaindole-1-carboxylic acid tert-butyl ester;1-(tert-Butoxycarbonyl)-7-azaindole, 1-(tert-Butoxycarbonyl)-1H-pyrrolo[2,3-b]pyridine;N-Boc-7-azaindole;1-BOC-Pyrrolo[2,3-b]pyridine;tert-Butyl 1H-pyrrolo[2,3-b]pyridine-1-carboxylate
• CAS NO: 138343-77-8
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218.25
• Mol File: 138343-77-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 327.159 °C at 760 mmHg
• Flash Point: 151.661 °C
• Appearance: /
• Density: 1.135 g/mL at 25 °C
• Vapor Pressure: 0.000206mmHg at 25°C
• Refractive Index: n20/D 1.546
• Storage Temp.: Room temperature.
• PKA: 2.90±0.30(Predicted)
• CAS DataBase Reference: 1-Boc-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-7-azaindole(138343-77-8)
• EPA Substance Registry System: 1-Boc-7-azaindole(138343-77-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 138343-77-8(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C12H14N2O2/c1-12(2,3)16-11(15)14-8-6-9-5-4-7-13-10(9)14/h4-8H,1-3H3

Upstream product

• 271-63-6 7-Azaindole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1028331-38-5 (Z)-2-bromo-3-(2-bromovinyl)pyridine 
• 4248-19-5 tert-butyl carbazate 
• 138343-75-6 tert-butyl (3-methylpyridin-2-yl)carbamate 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 138343-76-7 1-(tert-butoxycarbonyl)-2,3-dihydro-2-hydroxy-1H-pyrrolo<2,3-b>pyridine 

Downstream Products

• 2580027-30-9 1H-pyrrolo[2,3-b]pyridine-2-boronic acid pinacol ester 
• 1083181-25-2 2-bromo-1H-pyrrole[2,3-b]pyridine 
• 226085-17-2 tert-butyl 3-bromo-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 942070-47-5 2-methyl-2-propanyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine-1-carboxylate 
• 945256-29-1 3‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)‐1H‐pyrrolo[2,3‐b]pyridine 
• 271-63-6 7-Azaindole 

Relevant articles and documents

Synthesis method of 1H-pyrrolo[2,3-b]pyridine-2-boronic acid pinacol ester

The invention discloses a synthesis method of 1H-pyrrolo[2,3-b]pyridine-2-boronic acid pinacol ester, and belongs to the field of medicinal chemistry. The synthesis method comprises the following steps: reacting 7-azaindole serving as a raw material with di-tert-butyl dicarbonate to synthesize 1H-pyrrolo[2,3b]pyridine-1-carboxylic acid tert-butyl ester, reacting the 1H-pyrrolo[2,3b]pyridine-1-carboxylic acid tert-butyl ester with n-butyl lithium and 1,2-dibromotetrafluoroethane at low temperature to synthesize 2-bromo-1H-pyrrolo[2,3-b]pyridine, synthesizing 2-bromo-1H-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester, removing the protective group to obtain 2-bromo-1H-pyrrolo[2,3-b]pyridine, and reacting 2-bromo-1H-pyrrolo[2,3-b]pyridine with bi-pinacol borate under the catalytic action of transition metals to obtain the target product. The raw materials and reagents are cheap and easy to obtain, reaction conditions are mild, the safety is high, the cost is low, and the preparation method is easily applied to industrial batch production.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.